keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy metastatic breast cancer

keyword
https://www.readbyqxmd.com/read/29675680/a-randomized-double-blind-phase-2-study-of-ruxolitinib-or-placebo-in-combination-with-capecitabine-in-patients-with-advanced-her2-negative-breast-cancer-and-elevated-c-reactive-protein-a-marker-of-systemic-inflammation
#1
Joyce O'Shaughnessy, Angela DeMichele, Cynthia X Ma, Paul Richards, Denise A Yardley, Gail Shaw Wright, Kevin Kalinsky, Ronald Steis, Sami Diab, Gerard Kennealey, Ryan Geschwindt, Wei Jiang, Hope S Rugo
PURPOSE: The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] ≥ 1). METHODS: Patients with ≤ 2 prior chemotherapy regimens for advanced or metastatic disease or hormone receptor-positive patients with disease progression on prior hormonal therapies were randomized 1:1 to 21-day cycles of ruxolitinib (n = 76) or placebo (n = 73) plus capecitabine...
April 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29670855/current-therapies-for-human-epidermal-growth-factor-receptor-2-positive-metastatic-breast-cancer-patients
#2
REVIEW
Alexey A Larionov
The median survival of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) has more than doubled, since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 years in 2017. The initial generation of HER2-targeted therapies included trastuzumab with taxanes in the first line, followed by the addition of lapatinib and by a switch to another cytotoxic agent after progression. Results of CLEOPATRA, EMILIA, and TH3RESA trials have changed this clinical practice...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29663291/apatinib-a-review-in-advanced-gastric-cancer-and-other-advanced-cancers
#3
Lesley J Scott
Apatinib [AiTan™ (China); Rivoceranib® (global)] is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas...
April 16, 2018: Drugs
https://www.readbyqxmd.com/read/29660759/parp-inhibitors-in-breast-cancer-bringing-synthetic-lethality-to-the-bedside
#4
REVIEW
Anita A Turk, Kari B Wisinski
Individuals with breast and ovarian cancer susceptibility gene 1 (BRCA1) or BRCA2 germline mutations have a significantly increased lifetime risk for breast and ovarian cancers. BRCA-mutant cancer cells have abnormal homologous recombination (HR) repair of DNA. In these tumors, the base excision repair (BER) pathway is important for cell survival. The poly(adenosine diphosphate-ribose) polymerase (PARP) enzymes play a key role in BER, and PARP inhibitors are effective in causing cell death in BRCA-mutant cells while sparing normal cells-a concept called synthetic lethality...
April 16, 2018: Cancer
https://www.readbyqxmd.com/read/29651367/-lazarus-response-to-olaparib-in-a-virtually-chemonaive-breast-cancer-patient-carrying-gross-brca2-gene-deletion
#5
Vladimir M Moiseyenko, Vyacheslav A Chubenko, Fedor V Moiseyenko, Lyudmila A Zagorskaya, Yuliya A Zaytseva, Nataliya E Gesha, Evgeny N Zykov, Valeriya I Ni, Elena V Preobrazhenskaya, Anna P Sokolenko, Evgeny N Imyanitov
This report describes an estrogen receptor-positive breast cancer patient, who relapsed at two and a half years after the completion of adjuvant chemotherapy while being on the aromatase inhibition. Based on the clinical evidence for potential sensitivity of the tumor to hormone ablation, everolimus was added to continuing exemestane treatment. Oral chemotherapy was administered at further disease progression, however, it lasted only for 10 days due to rapidly deteriorating condition of the patient. BRCA test was performed just before the failure of endocrine therapy and revealed a gross deletion within BRCA2 gene...
February 4, 2018: Curēus
https://www.readbyqxmd.com/read/29650929/-a-case-of-her2-positive-occult-breast-cancer-presenting-as-swollen-axillary-lymphnodes
#6
Toshiyuki Ishiba, Goshi Oda, Tsuyoshi Nakagawa, Takumi Akashi, Yamato Yamashita, Tomoki Aburatani, Taichi Ogo, Yutaka Nakashima, Hironobu Baba, Naoaki Hoshino, Yoshinobu Nishioka, Tatsuyuki Kawano
Occult breast cancer, which develops as a metastatic lesion with no primary tumor detected in the breast, is a rare breast cancer. A 68-year-old female patient particularly complained of the presence of a right axillary mass. The mass in the right axilla was palpable, but no tumor was found in both the breasts on palpation, ultrasound examination, or MRI. Partial breast resection and axillary lymph node dissection were performed following a diagnosis of invasive ductal carcinoma by core needle biopsy. There was no mammary gland tissue present around the tumor due to the pathology of the disease, and the tumor was diagnosed as occult breast cancer...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29649281/classification-for-long-term-survival-in-oligometastatic-patients-treated-with-ablative-radiotherapy-a-multi-institutional-pooled-analysis
#7
Julian C Hong, Diandra N Ayala-Peacock, Jason Lee, A William Blackstock, Paul Okunieff, Max W Sung, Ralph R Weichselbaum, Johnny Kao, James J Urbanic, Michael T Milano, Steven J Chmura, Joseph K Salama
BACKGROUND: Radiotherapy is increasingly used to treat oligometastatic patients. We sought to identify prognostic criteria in oligometastatic patients undergoing definitive hypofractionated image-guided radiotherapy (HIGRT). METHODS: Exclusively extracranial oligometastatic patients treated with HIGRT were pooled. Characteristics including age, sex, primary tumor type, interval to metastatic diagnosis, number of treated metastases and organs, metastatic site, prior systemic therapy for primary tumor treatment, prior definitive metastasis-directed therapy, and systemic therapy for metastasis associated with overall survival (OS), progression-free survival (PFS), and treated metastasis control (TMC) were assessed by the Cox proportional hazards method...
2018: PloS One
https://www.readbyqxmd.com/read/29644491/update-on-parp-inhibitors-in-breast-cancer
#8
REVIEW
Alexandra S Zimmer, Mitchell Gillard, Stanley Lipkowitz, Jung-Min Lee
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat certain ovarian cancers, including those with gBRCAm and olaparib for treatment of gBRCAm breast cancers. Several PARPi are now under clinical development for breast cancer in the various treatment settings. Recently, two phase III trials of olaparib (OlympiaD) and talazoparib (EMBRACA) demonstrated 3-month progression-free survival improvement with PARPi compared to physician's choice single agent chemotherapy in metastatic gBRCAm breast cancer...
April 11, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29624641/feasibility-safety-and-efficacy-of-aerobic-training-in-pretreated-patients-with-metastatic-breast-cancer-a-randomized-controlled-trial
#9
Jessica M Scott, Neil M Iyengar, Tormod S Nilsen, Meghan Michalski, Samantha M Thomas, James Herndon, John Sasso, Anthony Yu, Sarat Chandarlapaty, Chau T Dang, Elizabeth A Comen, Maura N Dickler, Jeffrey M Peppercorn, Lee W Jones
BACKGROUND: The investigation of exercise training in metastatic breast cancer has received minimal attention. This study determined the feasibility and safety of aerobic training in metastatic breast cancer. METHODS: Sixty-five women (age, 21-80 years) with metastatic (stage IV) breast cancer (57% were receiving chemotherapy, and >40% had ≥ 2 lines of prior therapy) were allocated to an aerobic training group (n = 33) or a stretching group (n = 32)...
April 6, 2018: Cancer
https://www.readbyqxmd.com/read/29611759/experience-with-eribulin-in-patients-with-breast-cancer-and-cutaneous-metastases-case-studies
#10
Ruth Espinosa Aunión, Carmen Aida Ramírez Ruda, Carmela Rodríguez López, Teresa Curiel García, José Ángel García Saénz, Rafael López López
Skin localization occurs in about 25% of women with metastatic breast cancer and represents a major therapeutic challenge. Although clinical literature on response of cutaneous metastases to chemotherapy is scarce, good response to eribulin has been reported. Herein, the clinical courses of three women with skin lesions secondary to metastatic breast cancer are described. The first patient achieved a complete clinical response in skin metastases with good tolerability to fourth-line eribulin (progression-free survival [PFS]: 8...
March 2018: Future Oncology
https://www.readbyqxmd.com/read/29611755/experience-with-eribulin-in-hr-her2-metastatic-breast-cancer-including-a-male
#11
Maria Del Mar Muñoz Sánchez, Maria Del Carmen Soriano Rodríguez, Maria José Molina Garrido, Ana López-González, Andrés García-Palomo, Laura López-González, Maria Yéssica Plata Fernández, Natalia Luque Caro, Pedro Sánchez Rovira
Numerous patient- and disease-related factors must be considered when deciding a treatment approach for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Hormone therapy (HT) is generally the first option in the absence of compelling reasons for chemotherapy (e.g., rapidly progressive visceral disease). After failure of first-choice HT, alternative HT options are usually attempted until hormone resistance occurs and chemotherapy becomes the treatment of choice...
March 2018: Future Oncology
https://www.readbyqxmd.com/read/29611754/experience-with-eribulin-in-triple-negative-metastatic-breast-cancer-case-studies
#12
Maria Isabel Gallegos Sancho, Raúl Márquez-Vázquez, Alfonso Sánchez-Muñoz
Triple-negative breast cancers are defined as tumors negative for estrogen receptors, progesterone receptors and human EGFR2. These tumors exhibit diverse biological behavior and have a poor prognosis; chemotherapy is the mainstay of treatment. The first case involves a young woman with cerebral and cerebellar metastases who achieved a persistent objective response to fourth-line eribulin. In the second case, a woman who became metastatic during adjuvant therapy with anthracyclines and taxanes, and was refractory to capecitabine + bevacizumab, achieved a partial response and local symptom improvement with eribulin + bevacizumab...
March 2018: Future Oncology
https://www.readbyqxmd.com/read/29605174/significant-association-between-low-baseline-neutrophil-to-lymphocyte-ratio-and-improved-progression-free-survival-of-patients-with-locally-advanced-or-metastatic-breast-cancer-treated-with-eribulin-but-not-with-nab-paclitaxel
#13
Yoshimasa Miyagawa, Kazuhiro Araki, Ayako Bun, Hiromi Ozawa, Yukie Fujimoto, Tomoko Higuchi, Arisa Nishimukai, Ayako Kira, Michiko Imamura, Yuichi Takatsuka, Yasuo Miyoshi
INTRODUCTION: Although eribulin and nab-paclitaxel are chemotherapy agents widely used for locally advanced or metastatic breast cancer (MBC), their predictive factors remain unknown. Because the absolute neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic factor for early-stage breast cancer, we investigated its usefulness in terms of the eribulin or nab-paclitaxel treatment efficacy for MBC. PATIENTS AND METHODS: A total of 85 patients with MBC treated with eribulin (n = 59) or nab-paclitaxel (n = 26) were recruited...
March 8, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29595684/gastric-metastasis-from-invasive-lobular-breast-cancer-mimicking-primary-gastric-cancer-a-case-report
#14
Dae Hoon Kim, Seung-Myoung Son, Young Jin Choi
RATIONALE: Gastric metastasis from invasive lobular breast cancer is relatively rare, commonly presented among multiple metastases, several years after primary diagnosis of breast cancer. Importantly, gastric cancer that is synchronously presented with lobular breast cancer can be misdiagnosed as primary gastric cancer; therefore, accurate differential diagnosis is required. PATIENT CONCERNS: A 39-year-old woman was visited to our hospital because of right breast mass and progressive dyspepsia...
March 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29594360/a-phase-ii-multicenter-single-arm-trial-of-eribulin-as-first-or-second-line-chemotherapy-for-her2-negative-advanced-or-metastatic-breast-cancer-evaluation-of-efficacy-safety-and-patient-reported-outcomes
#15
Kosei Kimura, Mitsuhiko Iwamoto, Satoru Tanaka, Daigo Yamamoto, Katsuhide Yoshidome, Hiroyuki Ogura, Risa Terasawa, Nobuki Matsunami, Yuko Takahashi, Toshikatsu Nitta, Takashi Morimoto, Hiroya Fujioka, Kanako Kawaguchi, Kazuhisa Uchiyama
PURPOSE: Although eribulin is a suitable option for early-line treatment of metastatic breast cancer (MBC), data on first- or second-line use of eribulin for human epidermal growth factor receptor 2 (HER2)-negative MBC are still limited. Therefore, we conducted a phase II trial to investigate the efficacy and safety of eribulin for first- or second-line chemotherapy for HER2-negative MBC. MATERIALS AND METHODS: We performed a phase II, open-label, single-arm, multicenter study in Japan...
March 28, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29594207/patterns-of-loco-regional-failure-in-women-with-breast-cancer-treated-by-postmastectomy-conformal-electron-beam-radiation-therapy-pmert-large-scale-single-center-experience
#16
Gokoulakrichenane Loganadane, Zhen Xi, Hao Ping Xu, Noemie Grellier Adedjouma, Louis Bazire, Alain Fourquet, Youlia M Kirova
Purpose: To evaluate loco regional control and describe the patterns of loco regional failure in women with breast cancer irradiated by a previously described post-mastectomy highly conformal electron beam radiotherapy technique. Materials and methods: We included all women irradiated by PMERT for non-metastatic breast cancer (BC) between 2007 and 2011 in our department. All cases of bilateral BC were excluded. All patients who experienced loco regional recurrence have been studied...
June 2017: Clinical and Translational Radiation Oncology
https://www.readbyqxmd.com/read/29593098/administration-of-the-tablet-formulation-of-olaparib-in-patients-with-ovarian-cancer-practical-guidance-and-expectations
#17
REVIEW
Kathleen N Moore, Michael J Birrer
Olaparib is a poly(ADP-ribose) polymerase enzyme inhibitor that is approved for use in patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have received three or more prior lines of chemotherapy for maintenance treatment of recurrent OC that is in response to platinum-based chemotherapy regardless of BRCA mutation status and for human epidermal growth receptor factor 2-negative metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting...
March 28, 2018: Oncologist
https://www.readbyqxmd.com/read/29582690/olaparib-for-the-treatment-of-breast-cancer
#18
Gaia Griguolo, Maria Vittoria Dieci, Valentina Guarneri, PierFranco Conte
Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast cancer. Areas covered: This review gives an overview of available preclinical and clinical data regarding olaparib, including its chemistry, mechanism of action, pharmacokinetics and pharmacodynamics, and evidence supporting antitumor efficacy and safety profile in breast cancer patients...
March 27, 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29582584/dysregulation-of-metabolic-associated-pathways-in-muscle-of-breast-cancer-patients-preclinical-evaluation-of-interleukin-15-targeting-fatigue
#19
Joseph Bohlen, Sarah L McLaughlin, Hannah Hazard-Jenkins, Aniello M Infante, Cortney Montgomery, Mary Davis, Emidio E Pistilli
BACKGROUND: Breast cancer patients report a perception of increased muscle fatigue, which can persist following surgery and standardized therapies. In a clinical experiment, we tested the hypothesis that pathways regulating skeletal muscle fatigue are down-regulated in skeletal muscle of breast cancer patients and that different muscle gene expression patterns exist between breast tumour subtypes. In a preclinical study, we tested the hypothesis that mammary tumour growth in mice induces skeletal muscle fatigue and that overexpression of the cytokine interleukin-15 (IL-15) can attenuate mammary tumour-induced muscle fatigue...
March 26, 2018: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/29582246/current-treatment-patterns-among-postmenopausal-women-with-hr-her2-metastatic-breast-cancer-in-us-community-oncology-practices-an-observational-study
#20
Deborah Goldschmidt, Anand A Dalal, Hela Romdhani, Sneha Kelkar, Annie Guerin, Genevieve Gauthier, Eric Q Wu, Polly Niravath, Tania Small
INTRODUCTION: Recent approval of novel agents has changed the treatment landscape for post menopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (mBC). The objective of this study was to describe contemporary treatment patterns among postmenopausal women with HR+/HER2- mBC in the real-world setting. METHODS: Data were collected from 64 community oncologists in the US between February and June 2017 using an online medical records extraction tool...
March 26, 2018: Advances in Therapy
keyword
keyword
117545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"